Screening to Improve Survival in AL Amyloidosis

Status Completed

Clinical Trial Summary

The purpose of this study is to see whether certain genes may be linked with the development of AL amyloidosis in subjects 60 years of age or older with the blood disorders SMM and MGUS. A limited repertoire of immunoglobulin (Ig) variable region genes have been associated with AL amyloidosis. The clonal plasma cells of subjects with SMM and MGUS may express one of these Ig variable region genes indicating a risk of progression to AL amyloidosis and potentially enabling early diagnosis. We hope this study will help us begin to understand whether Ig variable region gene identification can be a useful tool for assessing a subject's risk of progression to AL amyloidosis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Amyloidosis
Immunoglobulin Light-chain Amyloidosis
Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Paraproteinemias
Smoldering Multiple Myeloma

Clinical Trial Details

NCT number	NCT04615572
Study type	Observational
Source	Tufts Medical Center
Contact
Status	Completed
Phase
Start date	August 28, 2020
Completion date	July 6, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01222286` - Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma	Phase 2
Withdrawn	`NCT00503763` - Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma	Phase 2
Active, not recruiting	`NCT02916771` - Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma	Phase 2
Completed	`NCT01955395` - Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma	N/A
Completed	`NCT01237054` - Imaging in MGUS, SMM and MM	Phase 2
Completed	`NCT02903381` - A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma	Phase 2
Active, not recruiting	`NCT03301220` - A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma	Phase 3
Active, not recruiting	`NCT03236428` - Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma	Phase 2
Completed	`NCT01718899` - Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma	Phase 1
Completed	`NCT00112827` - Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma	Phase 1/Phase 2
Completed	`NCT00099047` - Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma	Phase 2
Terminated	`NCT01248455` - A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma	Phase 2
Active, not recruiting	`NCT03289299` - Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant	Phase 2
Not yet recruiting	`NCT06365060` - Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Active, not recruiting	`NCT02415413` - Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma	Phase 2
Completed	`NCT01302886` - Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma	Phase 2
Recruiting	`NCT05841550` - The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma	Phase 1/Phase 2
Recruiting	`NCT06383143` - Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Active, not recruiting	`NCT02886065` - A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM	Phase 1
Withdrawn	`NCT01571726` - Imaging Studies and the Development of Multiple Myeloma	Phase 2